Independent, Centralized Image Review and Analyses Supporting Development of VK2809 to Treat NAFLD/NASH Introduction Non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH), is estimated to become the most common chronic liver condition in Western populations. This increased prevalence is related to the increase in lifestyle-related diseases – due to the shared risk factors of obesity, insulin sensitivity, and poor diet and exercise habits. However, the etiology of NAFLD/NASH is not well understood – the diseases’ multifactorial nature is a contributing factor and challenges drug development. Although sponsors are racing through Phase III trials, there has been limited success, and no drug is currently approved for treatment. Th

Join for free to read